CDTX vs DBVT vs HALO vs IMVT

For growth investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger pick with 37. 6% revenue growth year-over-year, versus -94. 5% for Cidara Therapeutics, Inc. (CDTX). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 25. 9x trailing P/E (8. 2x forward), making it the more compelling value choice. Analysts rate Cidara Therapeutics, Inc. (CDTX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cidara Therapeutics, Inc.

(CDTX) delivered a total return of +448. 0%, compared to -66. 6% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: HALO returned +598. 4% versus DBVT's -86. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 56β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 146% more volatile than HALO relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Halozyme Therapeutics, Inc.

(HALO) is pulling ahead at 37. 6% versus -94. 5% for Cidara Therapeutics, Inc. (CDTX). On earnings-per-share growth, the picture is similar: Halozyme Therapeutics, Inc. grew EPS -25. 4% year-over-year, compared to -409. 5% for Cidara Therapeutics, Inc.. Over a 3-year CAGR, HALO leads at 28. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Halozyme Therapeutics, Inc.

(HALO) is the more profitable company, earning 22. 7% net margin versus -133. 2% for Cidara Therapeutics, Inc. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -138. 1% for CDTX. At the gross margin level — before operating expenses — CDTX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DBVT: 130.

5% to $46. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +598. 4% 10Y return). Both have compounded well over 10 years (HALO: +598. 4%, DBVT: -86. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CDTX is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; HALO is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.